While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
List view / Grid view
A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of aggressive prostate cancer.
US researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer.
Researchers have identified a previously unrecognised form of hormone therapy-resistant prostate cancer.
A new screening assay could be used to identify new drugs to treat resistant forms of prostate cancer.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.